#USA #Boston #Field Medical #AF Symposium #PFA Technology

Field Medical Unveils Latest Trial Results for PFA Technology at AF Symposium 2026

Field Medical, Inc., a pioneering force in medical technology focused on cardiac solutions, has made a significant stride in the realm of pulsed field ablation (PFA). At the recently held AF Symposium 2026 in Boston, the company showcased compelling data from their first-in-human study, Field PULSE. This presentation shed light on the transformational potential of their cutting-edge ablation system designed for complex cardiac arrhythmias.

Innovative Approach to Cardiac Ablation

The FieldForce™ Ablation System represents a noteworthy advancement in the field of cardiology. With a focal, contact-sensing catheter, this system delivers a unique high-voltage, sub-second pulsed field waveform that facilitates instantaneous ablation. The impressive feature of this technology allows for effective point-by-point energy delivery, eliminating the need for prolonged contact between the catheter and tissue. Dr. Vivek Y. Reddy, the principal investigator of the study and an electrophysiologist at Mount Sinai in New York, emphasized that this groundbreaking methodology preserves the innate flexibility required during focal ablation procedures while enhancing their efficiency.

Key Findings from the Field PULSE Study

During the session, several remarkable outcomes from the Field PULSE study were presented, demonstrating the efficacy and safety of the new technology:
Instantaneous Energy Delivery: The system creates ablation lesions in less than 200 milliseconds. This rapid energy delivery allows for more efficient ablation processes, improving patient safety and comfort.
Procedural Efficiency: On average, the bilateral pulmonary vein isolation (PVI) took only 12.5 minutes, with the most efficient cases completed in just 7.7 minutes.
Durability of PV Isolations (PVI): Follow-up evaluations showed improved PVI durability over time - evidencing a 94.2% success rate by vein and an 84.6% success rate by patient.
Safety Outcomes: Importantly, there were no device-related serious adverse events reported during the trial, showcasing the safety profile of the FieldForce system. Additionally, patients undergoing evaluation via brain MRI displayed no silent cerebral lesions.

These findings not only enrich the clinical evidence surrounding the high-voltage focal PFA approach but also mark a significant expansion of its application beyond ventricular arrhythmias to include treatment for atrial fibrillation (AF).

Vision for the Future

According to Dr. Steven Mickelsen, founder and CTO of Field Medical, the results from the Field PULSE study validate their strategic approach to developing focused PFA technology. Their aim is to confront the fundamental limitations posed by existing ablation methods through robust data and innovative design. The ability to deliver ablation points rapidly minimizes the dependence on a stable catheter position, effectively enhancing treatment outcomes for patients suffering from complex arrhythmias.

The Field PULSE data were highlighted during the Late Breaking Clinical Trials session at the AF Symposium, showcasing the scientific advancements made in this vital area of medical treatment. For additional insights into the biophysics involved in pulsed field ablation, a specific session on February 6 featured sessions led by leading experts in the field.

Field Medical’s pioneering work in this domain underlines its commitment to advancing the treatment of cardiac conditions, ensuring better outcomes for patients. With the FieldForce™ Ablation System, the company positions itself as a leader in the evolution of cardiac care technology.

As Field Medical continues its journey toward broader applications of PFA technologies, the healthcare community remains hopeful for more innovations that align with improved patient care and effective treatment methodologies. To learn more about their projects, visit Field Medical's website.